Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Holdings Lowered by Corebridge Financial Inc.

Corebridge Financial Inc. reduced its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 69,716 shares of the company’s stock after selling 5,262 shares during the quarter. Corebridge Financial Inc.’s holdings in Xeris Biopharma were worth $236,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its stake in shares of Xeris Biopharma by 6.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after acquiring an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after acquiring an additional 5,500 shares during the last quarter. Goldstein Advisors LLC raised its position in shares of Xeris Biopharma by 24.2% during the fourth quarter. Goldstein Advisors LLC now owns 37,800 shares of the company’s stock worth $128,000 after purchasing an additional 7,375 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Xeris Biopharma by 4.3% during the fourth quarter. Rhumbline Advisers now owns 180,964 shares of the company’s stock valued at $613,000 after purchasing an additional 7,408 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on XERS shares. HC Wainwright restated a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler restated a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum raised their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.10.

Xeris Biopharma Stock Performance

Shares of XERS opened at $4.16 on Friday. The company has a market capitalization of $640.39 million, a PE ratio of -9.24 and a beta of 1.37. The company’s 50 day moving average price is $4.39 and its 200 day moving average price is $3.65. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $6.07.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.